By Diagnostics World Staff
September 4, 2024 | Today, Proscia announced a real-world data offering on its Concentriq platform comprising a diverse repository of over 10 million whole slide images enhanced with structured data from molecular tests, pathology reports, laboratory tests, and next-generation sequencing across therapeutic areas. The data are enriched with quantification of hundreds to thousands of AI-computed features to help generate deeper insights.
“Life Sciences organizations are turning to real-world data and AI to answer their biggest questions and advance precision medicine from bench to bedside,” said David West, Proscia’s CEO, in a press release announcing the new product offering. “The interplay among whole slide images, clinical and genomic data, and novel therapies and diagnostics will only grow stronger. Proscia is uniquely positioned at this intersection to help our customers deliver the next generation of patient care.”
The data have been used in a year-long pilot program with a subset of life sciences partners to demonstrate its impact in practice, the company said. Based on user experience, the cohorts were designed to include diverse data modalities and can be tailored to specific to therapeutic areas of need.
“What we’ve experienced over the past year has only strengthened our confidence in the power of multimodal data incorporating pathology images,” said Ross Cantor, Vice President, Data Strategy & Partnerships at Proscia, in a blog post today.
The data are available as cohorts across various therapeutic areas tailored to meet diverse research requirements aligned with drug development pipelines. They are accessed through the Concentriq enterprise pathology platform, made available as an add-on through a subscription model.
Scientists can leverage them in their workflows to unlock new insights from whole slide images with Proscia’s precision medicine AI portfolio, and develop proprietary AI models, including precision diagnostics, with the platform’s developer tools.
Precision diagnostics developed with the RWD dataset can be deployed on the platform to Proscia’s growing network that includes national laboratories, health systems, and biopharma organizations. In turn, these AI-enabled tests can be easily distributed into clinical practice to match patients with the best treatments, the company said.